CAR-T Meeting 2022 | Risk factors associated with TA-TMA in patients with GvHD
In this video, Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, discusses risk factors associated with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with graft versus host disease (GvHD). Dr Gavriilaki explains some predictors associated with TA-TMA, including viral infections, GvHD, and myeloablative conditioning (TBI). Dr Gavriilaki also discusses some research which suggests that there may be a genetic susceptibility to TA-TMA, and that complement inhibitors such as eculizumab may be of benefit to patients in this scenario. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi.
Dr Gavriilaki has received research support from Jazz Pharmaceuticals.
